Company intelligence / Profile preview

Astrocyte Pharmaceuticals Inc.

Groton, Connecticut, United Statesastrocytepharma.com ↗

Ownership: Private
Development stage: Other

Overview

Astrocyte Pharmaceuticals has completed two Phase 1 safety trials in Europe involving 80 participants with no significant adverse effects or safety concerns. Their lead candidate AST-004 demonstrated significant efficacy in preclinical studies, including preserving up to 45% more brain tissue in a non-human primate model of stroke. The FDA has cleared their IND application for AST-004 for acute ischemic stroke, allowing them to proceed to Phase 2 clinical trials[8].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

AST-004

2 more assets in the full pipeline.

Partnerships

Medical Technology Enterprise Consortium (MTEC)U.S. Army Medical Research and Development Command (USAMRDC)BrightFocus Foundation

Beyond the preview

Go deeper on Astrocyte Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Astrocyte Pharmaceuticals Inc..